Cure Parkinson’s and Alzheimer’s Research UK announce a partnership
Cure Parkinson’s and Alzheimer’s Research UK are working on an initiative that could pave the way for innovative neurodegenerative treatments. There is a growing recognition that tackling neurodegenerative diseases could benefit from a collaborative, cross-disease approach. We are recognising the overlap in underlying biological...
Learn more
A year in review: our 2021 research funding update
Despite a challenging year caused by COVID-19, Cure Parkinson’s has not been deterred in its efforts to identify and progress novel therapies to slow, stop and reverse Parkinson’s in 2021.
Tackling toxic alpha-synuclein
Three major lines of clinical investigation are currently underway to determine if stopping the clustering of alpha-synuclein in Parkinson’s can help to slow down the progression of the disease.
The Anle138b Trial
This clinical trial is testing a small molecule called Anle138b to assess its potential to inhibit alpha-synuclein masses accumulating. In Parkinson’s, alpha-synuclein, which is abundant in nerve cells, begins clumping together (or aggregating) and it is believed that this process could be toxic. This trial, it is hoped, will slow-down…
PD Frontline
As research has expanded in the area of Parkinson’s genetics, researchers have been able to uncover a number of genes which have been linked to an increased risk of developing Parkinson’s. PD Frontline is a remote study offering online genetic testing for people with Parkinson’s,…
The PROSEEK trial of KO706
Sun Pharma Advanced Research Company (SPARC) is conducting a phase 2 clinical trial to evaluate the safety and effectiveness of its experimental c-Abl inhibitor KO706 in people with early Parkinson’s.